Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LOBSTER: Short vs Long-term Adjuvant ADT with Salvage RT
NCT04242017Phase 3Recruiting
- Sponsor
- UZ Leuven
- Start
- Jul 2020
- Primary completion
- Feb 2026
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of triptorelin in prostate cancer (PCa) (2 arms), sponsored by UZ Leuven. Primary endpoint: Metastasis-free survival at 5 years. Started Jul 2020; status: recruiting.
02
Drugs
triptorelin
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04242017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04242017.